Ketamine as an adjuvant to opioids for cancer pain

  • Bell R
  • Eccleston C
  • Kalso E
75Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

You may have access to this PDF.

Abstract

This is an update of the original review published in Issue 1, 2003. Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of cancer pain, particularly when opioids alone prove to be ineffective. Ketamine is known to have psychotomimetic (including hallucinogenic), urological and hepatic adverse effects.

Cite

CITATION STYLE

APA

Bell, R. F., Eccleston, C., & Kalso, E. A. (2012). Ketamine as an adjuvant to opioids for cancer pain. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.cd003351.pub2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free